Fig. 4
From: Nanoparticles for MRI-guided radiation therapy: a review
(Reprinted with permission from Verry et al. (2021), copyright 2021, Elsevier)
T1-weighted MRI scans (3Â T field strength) for 2 patients in the NANORAD-1 trial, taken prior to injection of AGuIX (left) and 2Â h later (right) (green arrows point to metastatic tumour deposits), that demonstrate AGuIX accumulation post-injection via T1 contrast enhancement, most visible for the higher dose case. The 3D view demonstrates digital reconstruction of contrast uptake (colour bar)